Tech Company Financing Transactions

Omega Therapeutics Funding Round

BlackRock, Cowen Capital Partners and Fidelity Management & Research Company participated in a $126 million Series C funding round for Omega Therapeutics. The financing round was announced on 3/31/2021.

Transaction Overview

Company Name
Announced On
3/31/2021
Transaction Type
Venture Equity
Amount
$126,000,000
Round
Series C
Proceeds Purpose
Proceeds from the financing will be used to support the advancement of Omega's lead epigenomic controller candidate, OTX-2002, and to advance the next wave of novel pipeline therapeutics that it expects to be generated by the company's proprietary Omega Epigenomic Programming platform, with an initial focus in oncology, regenerative medicine, inflammation, autoimmune, metabolic and rare genetic diseases.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
20 Acorn Park Dr.
Cambridge, MA 02140
USA
Email Address
Overview
At Omega Therapeutics, we interrogate the central dogma to target the biological root of disease and change its course without altering nucleic acid sequences or the genetic code. We are focused on precision tuning to activate the human genome's native capacity to treat and cure diseases -- ultimately allowing for the advancement of medicine.
Profile
Omega Therapeutics LinkedIn Company Profile
Social Media
Omega Therapeutics Company Twitter Account
Company News
Omega Therapeutics News
Facebook
Omega Therapeutics on Facebook
YouTube
Omega Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mahesh Karande
  Mahesh Karande LinkedIn Profile  Mahesh Karande Twitter Account  Mahesh Karande News  Mahesh Karande on Facebook
Chief Financial Officer
Roger Sawhney
  Roger Sawhney LinkedIn Profile  Roger Sawhney Twitter Account  Roger Sawhney News  Roger Sawhney on Facebook
Chief Scientific Officer
Thomas McCauley
  Thomas McCauley LinkedIn Profile  Thomas McCauley Twitter Account  Thomas McCauley News  Thomas McCauley on Facebook
Vice President
Jeffrey Kopacz
  Jeffrey Kopacz LinkedIn Profile  Jeffrey Kopacz Twitter Account  Jeffrey Kopacz News  Jeffrey Kopacz on Facebook
Vice President
Joseph Newman
  Joseph Newman LinkedIn Profile  Joseph Newman Twitter Account  Joseph Newman News  Joseph Newman on Facebook
Vice President
Sivakesava Sakhamuri
  Sivakesava Sakhamuri LinkedIn Profile  Sivakesava Sakhamuri Twitter Account  Sivakesava Sakhamuri News  Sivakesava Sakhamuri on Facebook
VP - Bus. Development
Chinmaya Rath
  Chinmaya Rath LinkedIn Profile  Chinmaya Rath Twitter Account  Chinmaya Rath News  Chinmaya Rath on Facebook
VP - Finance
Barbara Chan
  Barbara Chan LinkedIn Profile  Barbara Chan Twitter Account  Barbara Chan News  Barbara Chan on Facebook
VP - Human Resources
Ann Darda
  Ann Darda LinkedIn Profile  Ann Darda Twitter Account  Ann Darda News  Ann Darda on Facebook


 

 

Browse more venture capital transactions:

Prev: 3/31/2021: Pyxis Oncology venture capital transaction
Next: 3/31/2021: Ambi Robotics venture capital transaction

 

Share this article

 


Where The Data Comes From

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary